Testing early response to Eylea 8mg for wet AMD
Part of Eyes & vision clinical trials.
This study looks at how quickly fluid in the retina clears after starting treatment with a higher dose of Eylea (aflibercept 8mg) for wet age-related macular degeneration (AMD). It aims to understand if early fluid changes can predict long-term outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have active wet AMD with fluid under or inside the retina.
- The scar tissue in your eye covers less than half of the affected area.
- Your vision in the study eye is 20/320 or better (around 23 letters on an eye chart).
- You have not had any prior eye injections for wet AMD or other treatments like laser or photodynamic therapy.
- You have not taken systemic anti-VEGF medications (like Avastin) before.
- You are not pregnant, nursing, or planning to become pregnant, and you use reliable birth control if you could become pregnant.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if switching to a higher dose of aflibercept (Eylea) can help people with wet age-related macular degeneration (AMD) who need frequent eye injections. If you've been on other anti-VEGF injections for over a year and still need them more often than every 12 weeks, this study might offer a new option.
This trial tests a new medicine called RBS-001, given as an eye injection, against an approved treatment (Eylea) for wet age-related macular degeneration (AMD). Wet AMD causes rapid vision loss due to abnormal blood vessels leaking fluid in the back of the eye; this study aims to see if the new drug works as well as the current standard.
This study tests whether switching to a higher dose of aflibercept (Eylea) is safe and effective for people with wet age-related macular degeneration who are already receiving standard-dose aflibercept. The goal is to see if the higher dose can better control the disease and possibly extend the time between injections.
This study compares two eye injection treatments for wet age-related macular degeneration (AMD), a condition that causes vision loss. The trial aims to see if the new drug GNR-139 works as well as the standard treatment Eylea.
This study tests a higher dose of a drug called aflibercept, given as eye injections, for people with untreated wet age-related macular degeneration (AMD). The goal is to see if it can improve vision and how often it needs to be given.
This study tests whether a new eye injection called ABP 938 works as well as or better than the current standard treatment (Eylea) for wet age-related macular degeneration—a condition that causes vision loss in the center of your sight. You would receive injections into your eye every month for a year.
Hear when a new Age-Related Macular Degeneration (AMD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.